← Back to Screener
Senti Biosciences Holdings, Inc. Common Stock (SNTI)
Price$0.97
Value ScoreF
Growth ScoreF
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-64.63%
Price vs S&P 500 (4W)-2.06%
VGM Score18.41
Market Capitalization$30.07M
All Metrics
Book Value / Share (Quarterly)$0.08
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-82.75%
Cash Flow / Share (Quarterly)$-1.19
Price vs S&P 500 (YTD)-15.33%
Net Profit Margin (TTM)-49178.95%
EPS (TTM)$-1.92
10-Day Avg Trading Volume0.20M
EPS Excl Extra (TTM)$-1.92
Revenue Growth (5Y)-47.77%
EPS (Annual)$-2.73
ROI (Annual)-1099.27%
Net Profit Margin (5Y Avg)-57781.84%
Cash / Share (Quarterly)$0.29
ROA (Last FY)-119.94%
EBITD / Share (TTM)$-1.97
ROE (5Y Avg)-289.37%
Operating Margin (TTM)-61189.47%
Cash Flow / Share (Annual)$-1.41
P/B Ratio11.72x
P/B Ratio (Quarterly)9.86x
Net Income / Employee (Annual)$-1,575,300
EV / Revenue (TTM)556.11x
Net Interest Coverage (TTM)-30.43x
ROA (TTM)-97.86%
EPS Incl Extra (Annual)$-2.73
Current Ratio (Annual)1.67x
Quick Ratio (Quarterly)0.57x
3-Month Avg Trading Volume0.18M
52-Week Price Return-72.88%
Revenue / Employee (TTM)$1,000
P/S Ratio (Annual)1366.69x
Asset Turnover (Annual)0.00x
52-Week High$3.88
Operating Margin (5Y Avg)-64708.33%
EPS Excl Extra (Annual)$-2.73
CapEx CAGR (5Y)-29.94%
26-Week Price Return-56.71%
Quick Ratio (Annual)1.31x
13-Week Price Return2.91%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.04x
Enterprise Value$21.13M
Revenue / Share Growth (5Y)-62.20%
Asset Turnover (TTM)0.00x
Revenue / Employee (Annual)$600
Pretax Margin (Annual)-279263.64%
Cash / Share (Annual)$0.53
3-Month Return Std Dev78.79%
Net Income / Employee (TTM)$-1,321,700
ROE (Last FY)-1099.27%
EPS Basic Excl Extra (Annual)$-2.73
Receivables Turnover (TTM)0.25x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.92
Receivables Turnover (Annual)0.09x
ROI (TTM)-503.79%
P/S Ratio (TTM)791.24x
Pretax Margin (5Y Avg)-57838.39%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)-97.25%
Year-to-Date Return-7.17%
5-Day Price Return-1.52%
EPS Normalized (Annual)$-2.73
ROA (5Y Avg)-64.55%
Net Profit Margin (Annual)-279263.64%
Month-to-Date Return1.45%
EBITD / Share (Annual)$-2.94
Operating Margin (Annual)-312631.82%
ROI (5Y Avg)-289.29%
EPS Basic Excl Extra (TTM)$-1.92
P/B Ratio (Annual)4.89x
Pretax Margin (TTM)-49178.95%
Book Value / Share (Annual)$0.18
Price vs S&P 500 (13W)-5.34%
Beta2.09x
Revenue / Share (TTM)$0.00
ROE (TTM)-503.79%
52-Week Low$0.77
vGradeF
gGradeF
mGradeC
vgmGradeF
Show chart for
Earnings Surprise History
Q1 26-0.36est. -0.37
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.20
4.20
4.20
4.20
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SNTISenti Biosciences Holdings, Inc. Common Stock | F | F | C | $0.97 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Senti Biosciences is a clinical-stage biotech company developing CAR-NK cell therapies—engineered cancer treatments controlled by its proprietary gene circuit platform. Its approach targets cancer cells while preserving healthy tissue, aiming to reduce treatment side effects. Lead candidates include SENTI-202 for various cancers and SENTI-301A for hepatocellular carcinoma.